JP5926243B2 - 経口薬物療法のための方法および組成物 - Google Patents

経口薬物療法のための方法および組成物 Download PDF

Info

Publication number
JP5926243B2
JP5926243B2 JP2013513002A JP2013513002A JP5926243B2 JP 5926243 B2 JP5926243 B2 JP 5926243B2 JP 2013513002 A JP2013513002 A JP 2013513002A JP 2013513002 A JP2013513002 A JP 2013513002A JP 5926243 B2 JP5926243 B2 JP 5926243B2
Authority
JP
Japan
Prior art keywords
cancer
drug
subject
methylol
taurolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013513002A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013527224A (ja
JP2013527224A5 (enExample
Inventor
フィルマン，ロルフ・ベー
ガイストリヒ，ペーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geistlich Pharma AG
Original Assignee
Geistlich Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geistlich Pharma AG filed Critical Geistlich Pharma AG
Publication of JP2013527224A publication Critical patent/JP2013527224A/ja
Publication of JP2013527224A5 publication Critical patent/JP2013527224A5/ja
Application granted granted Critical
Publication of JP5926243B2 publication Critical patent/JP5926243B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2013513002A 2010-06-01 2011-06-01 経口薬物療法のための方法および組成物 Active JP5926243B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35018310P 2010-06-01 2010-06-01
US61/350,183 2010-06-01
US37031510P 2010-08-03 2010-08-03
US61/370,315 2010-08-03
PCT/IB2011/001539 WO2011151722A2 (en) 2010-06-01 2011-06-01 Methods and compositions for oral pharmaceutical therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016037487A Division JP2016155826A (ja) 2010-06-01 2016-02-29 経口薬物療法のための方法および組成物

Publications (3)

Publication Number Publication Date
JP2013527224A JP2013527224A (ja) 2013-06-27
JP2013527224A5 JP2013527224A5 (enExample) 2014-07-17
JP5926243B2 true JP5926243B2 (ja) 2016-05-25

Family

ID=45067142

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013513002A Active JP5926243B2 (ja) 2010-06-01 2011-06-01 経口薬物療法のための方法および組成物
JP2016037487A Withdrawn JP2016155826A (ja) 2010-06-01 2016-02-29 経口薬物療法のための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016037487A Withdrawn JP2016155826A (ja) 2010-06-01 2016-02-29 経口薬物療法のための方法および組成物

Country Status (9)

Country Link
US (1) US9028866B2 (enExample)
EP (1) EP2575783B1 (enExample)
JP (2) JP5926243B2 (enExample)
CN (1) CN103118669B (enExample)
AU (1) AU2011262308B2 (enExample)
BR (1) BR112012030641B8 (enExample)
CA (1) CA2801309C (enExample)
ES (1) ES2614878T3 (enExample)
WO (1) WO2011151722A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301374B2 (en) * 2012-05-15 2016-03-29 Koninklijke Philips N.V. Control of lighting devices
US20190381060A1 (en) 2016-01-11 2019-12-19 Cormedix Inc. Taurolidine treatment for myc-expressing tumors in mammalian bodies
CA3010981C (en) * 2016-01-11 2024-09-17 Cormedix Inc. Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers
US20190381058A1 (en) * 2016-01-11 2019-12-19 Cormedix Inc. Methods and compositions for treating neuroblastoma in a juvenile mammalian body
US11541061B2 (en) 2016-01-11 2023-01-03 Cormedix Inc. Neuroblastoma treatment with taurolidine hydrolysis products
PL3709979T3 (pl) 2017-11-17 2025-03-24 Evonik Operations Gmbh Sposób wytwarzania powlekanej kapsułki twardej
CN113347976A (zh) * 2018-08-28 2021-09-03 科医公司 用牛磺罗定水解产物进行的神经母细胞瘤治疗
WO2020047530A1 (en) * 2018-08-31 2020-03-05 Cormedix Inc. Taurolidine treatment for myc-expressing tumors in mammalian bodies
WO2020234833A1 (en) 2019-05-22 2020-11-26 Geistlich Pharma Ag Method for treating, preventing, inhibiting or reducing cytokine release
US20220323452A1 (en) * 2019-05-22 2022-10-13 Geistlich Pharma Ag Methods and compositions for inhibiting gapdh
CN111671758A (zh) * 2020-07-06 2020-09-18 长春迈灵生物工程有限公司 牛磺罗定在制备抗hiv病毒药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210083A (en) 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
US5972933A (en) * 1998-01-08 1999-10-26 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating microbial infections
US6555534B1 (en) * 1998-09-11 2003-04-29 Medpointe Healthcare Inc. Method and compositions for the control or eradication of Helicobacter pylori
US6251896B1 (en) * 1999-03-24 2001-06-26 Carter-Wallace, Inc. Compositions and methods for the management of Crohn's disease
WO2001013957A2 (en) * 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
EP1246617B1 (en) * 1999-12-06 2006-09-13 Rhode Island Hospital Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of ovarian cancer
US20020004502A1 (en) * 2000-01-05 2002-01-10 Redmond H. Paul Treatment of inflammatory bowel disease
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
AU779362B2 (en) * 2000-10-27 2005-01-20 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
JP5502254B2 (ja) * 2001-01-31 2014-05-28 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング 少なくとも２種類の異なる被覆ペレット形から成る多粒子剤形
US20030092707A1 (en) * 2001-10-19 2003-05-15 Redmond H. Paul Treatment of breast cancer
EP2260845A3 (fr) 2002-06-21 2012-08-22 L'Oréal Utilisation de polyphénol pour le traitement de l'alopécie
US20060198886A1 (en) * 2005-03-01 2006-09-07 Jenkins Richard B Medicament having coated methenamine combined with acidifier
EA015781B1 (ru) * 2005-10-21 2011-12-30 Панацея Биотек Лимитед Композиции для лечения рака
ATE414518T1 (de) * 2006-07-25 2008-12-15 Claus Herdeis Herstellung von antimikrobiellen formulierungen unter verwendung von 7-oxa-2-thia 1,5- diazabicycloä3.3.1ünonan-2,2-dion

Also Published As

Publication number Publication date
CA2801309C (en) 2018-07-17
US20130089606A1 (en) 2013-04-11
BR112012030641B8 (pt) 2022-06-14
CA2801309A1 (en) 2011-12-08
AU2011262308A1 (en) 2013-01-10
JP2013527224A (ja) 2013-06-27
HK1183228A1 (zh) 2013-12-20
AU2011262308B2 (en) 2014-07-31
WO2011151722A2 (en) 2011-12-08
US9028866B2 (en) 2015-05-12
CN103118669B (zh) 2016-01-13
JP2016155826A (ja) 2016-09-01
BR112012030641B1 (pt) 2022-05-24
BR112012030641A2 (pt) 2016-08-16
ES2614878T3 (es) 2017-06-02
WO2011151722A3 (en) 2012-05-24
EP2575783B1 (en) 2017-01-11
EP2575783A2 (en) 2013-04-10
CN103118669A (zh) 2013-05-22

Similar Documents

Publication Publication Date Title
JP2016155826A (ja) 経口薬物療法のための方法および組成物
US12059397B2 (en) Calcium lactate compositions and methods of use
EP3843722B1 (en) Pharmaceutical composition comprising antiplatelet agent and gastric acid secretion inhibitor
CN101360495B (zh) 对癌症病人给药mTOR抑制剂
EA001760B1 (ru) Микрокапсулы, содержащие цис-платину
US20200397726A1 (en) Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage forms
JP6647204B2 (ja) 異常な細胞成長を処置するための組成物および方法
US20260014124A1 (en) Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
JP2013527224A5 (enExample)
KR20190040996A (ko) 간세포성 암종의 치료를 위한 조합 요법
JP7704690B2 (ja) 抗癌化合物ｅ７７６６の治療コンプライアンスを向上させるシステム
CN107334767A (zh) 一种哒嗪酮类化合物在肿瘤治疗中的应用
CN1329506A (zh) 具有改善的治疗范围的、含核苷酸合成抑制剂的制剂
JP4707668B2 (ja) オキソプラチン、その塩および誘導体を含む医薬組成物
JP7825575B2 (ja) 標的化放出リファキシミン組成物
US20040258751A1 (en) Composition containing ribavirin and use thereof
HK1183228B (en) Methods and compositions for oral pharmaceutical therapy
CN107137403B (zh) 一种pi3k/mtor抑制剂在制备治疗胰腺癌的药物中的用途
CN119454969A (zh) 含pd-l1小分子抑制剂的药物组合及其应用
WO2025241959A1 (zh) 抗体药物偶联物在预防或治疗疾病中的应用
AU2021228654A1 (en) Compositions and methods for treating cancer and tumor
BR112020008756A2 (pt) composições farmacêuticas orais de lorazepam resistentes a álcool

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20130124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150804

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160218

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160311

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160405

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160421

R150 Certificate of patent or registration of utility model

Ref document number: 5926243

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250